• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CSPC Pharmaceutical Group (SEHK:1093) Gains Attention On Pipeline Progress And AstraZeneca Tie Up

    Simply Wall St·07/14/2026 10:27:37
    語音播報

    CSPC Pharmaceutical Group (SEHK:1093) is back in focus after announcing progress across several drug candidates, including new clinical trials in hyperlipidaemia and non small cell lung cancer, as well as a research collaboration with AstraZeneca.

    See our latest analysis for CSPC Pharmaceutical Group.

    Against this backdrop of new trials and the AstraZeneca partnership, CSPC Pharmaceutical Group’s share price has risen about 12.0% over the past month but is still down around 14.1% over three months. The 3 year total shareholder return of 44.96% contrasts with a modest decline of 1.99% over the past year, suggesting longer term holders have seen gains even as shorter term momentum has been mixed.

    If this kind of pipeline activity catches your eye, it may be worth broadening your search to other healthcare related growth ideas using our screener for 127 healthcare AI stocks

    After a 12% rebound, and with CSPC Pharmaceutical Group still trading well below both analyst targets and intrinsic value estimates, the real focus now is where fair value sits within that spread and how much room is left.

    Price-to-Earnings of 24.6x: Is it justified?

    CSPC Pharmaceutical Group is trading on a P/E of 24.6x, which puts a clear premium on the current HK$8.11 share price relative to several benchmarks.

    The P/E ratio compares the share price to earnings per share and is often used for profitable healthcare companies where earnings forecasts are available. In this case, earnings are forecast to grow 14.56% per year, which may help explain why the market is willing to pay more for each dollar of current profit.

    However, that 24.6x multiple is higher than the estimated fair P/E of 19.6x. This suggests investors are currently paying more than the level the SWS fair ratio indicates the market could gravitate toward. On top of that, CSPC Pharmaceutical Group’s P/E is also higher than the Hong Kong pharmaceuticals industry average of 13.4x. This shows the stock is priced at a sizeable premium even within its own sector.

    Explore the SWS fair ratio for CSPC Pharmaceutical Group

    Result: Price-to-Earnings of 24.6x (OVERVALUED)

    However, CSPC Pharmaceutical Group still faces risks, including recent one-year and year-to-date share price declines, as well as execution uncertainty around its broad drug portfolio.

    Find out about the key risks to this CSPC Pharmaceutical Group narrative.

    Another View: SWS DCF Model Points to Upside

    While the P/E of 24.6x suggests CSPC Pharmaceutical Group looks expensive against its fair ratio and the Hong Kong pharmaceuticals sector, the SWS DCF model tells a different story. With the share price at HK$8.11 versus an estimated future cash flow value of HK$18.38, the stock is described as trading about 55.9% below that fair value line. The tension here is clear. Which signal do you treat as more important when the market is this split?

    Look into how the SWS DCF model arrives at its fair value.

    1093 Discounted Cash Flow as at Jul 2026
    1093 Discounted Cash Flow as at Jul 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CSPC Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 219 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    With CSPC Pharmaceutical Group pulling in mixed signals on value and sentiment, it may be useful to act promptly and stress test the data against your own expectations using our breakdown of 2 key rewards and 1 important warning sign

    Looking for more investment ideas beyond CSPC Pharmaceutical Group?

    If CSPC Pharmaceutical Group has sharpened your focus on quality opportunities, do not stop here. Broaden your watchlist with fresh stocks uncovered by the Simply Wall St screener.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.